Latest News
Conference Coverage
Regorafenib: New option for advanced gastroesophageal cancer?
Regorafenib significantly improves survival, compared with placebo, in patients with refractory AGOC, researchers report at ASCO GI.
Feature
Don’t cross the friends line with patients
A physician’s life can be lonely. So, when a patient invites you for coffee or a game of pickleball, do you accept?
Latest News
How should PRAME be used to evaluate melanocytic lesions?
One potential pitfall is that sun-damaged melanocytes may express PRAME.
From the Journals
More type 2 diabetes deaths from cancer than heart disease
In people with type 2 diabetes, cancer screening should get at least as much attention as CVD prevention.
Commentary
75 years: A look back on the fascinating history of methotrexate and folate antagonists
Dr. David Warmflash recounts how the meandering path of early research into chemotherapy for hematologic malignancies later led to methotrexate’s...
From the Journals
Severe health diagnoses drive suicide risk
The study included low-survival cancers, chronic ischemic heart disease, COPD, and degenerative neurological disease.
Feature
Canadian guidance recommends reducing alcohol consumption
Consuming no drinks per week has benefits.
From the Journals
Over half of ED visits from cancer patients could be prevented
The number of potentially preventable ED visits documented each year increased over the period that the authors of the new research studied.
Conference Coverage
Palliative radiotherapy successfully reduces end-stage liver cancer pain
Small study shows low-dose radiotherapy improves both pain and survival in hepatocellular carcinoma.
From the Journals
VEXAS syndrome: More common, variable, and severe than expected
A large U.S. analysis found that this newly discovered genetic disease has a estimated prevalence of 1 in 4,269 in men older than 50.
From the Journals
Does appendectomy raise the risk for colorectal cancer?
Researchers observed a 73% increase in CRC risk among appendectomy cases, compared with controls over a 20-year follow-up.